Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2007
08/02/2007WO2007085556A2 Use of 4-imidazole derivatives for cns disorders
08/02/2007WO2007085540A1 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives
08/02/2007WO2007085498A1 Pharmaceutical forms in film form for use in the mouth (wafers)
08/02/2007WO2007085469A1 Acyclic sulfamide derivatives
08/02/2007WO2007085451A2 3,5-di (aryl or heteroaryl) isoxazoles and 1, 2, 4-oxadiazoles as s1p1 receptor agonists, immunosuppresssive and anti -inflammatory agents
08/02/2007WO2007085420A1 Medicament comprising a hormone combination
08/02/2007WO2007085413A2 Treatment of transient ischaemic attack
08/02/2007WO2007085399A1 Use of a combination of valsartan and a calcium channel blocker in the treatment of insufficient blood flow and cerebral functional disorders
08/02/2007WO2007085370A1 9-(dimethylamino)-methyl-10-hydroxy-camptothecin lipidester derivatives
08/02/2007WO2007085357A1 Cyclourea compounds as calcium channel blockers
08/02/2007WO2007085205A1 Pyrrole substituted 2-indolinone derivatives, the preparation methods and medical uses thereof
08/02/2007WO2007085204A1 γ-BUTYROLACTONE COMPOUNDS, THE PREPARATION METHODS AND MEDICAL USES THEREOF
08/02/2007WO2007085203A1 New substituted pentabasic azaheterocyclic compounds and its use of treating protein aging disease
08/02/2007WO2007085202A1 Oxamic acid derivatives,preparation methods and medical uses thereof
08/02/2007WO2007085188A1 Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors
08/02/2007WO2007085136A1 1,3-benzodioxolecyclopentene derivates, preparation process and medical uses thereof
08/02/2007WO2007085135A1 1,3-benzodioxolecyclopentene-2,2-dicarboxylic acid derivates, preparation process and medical uses thereof
08/02/2007WO2007085127A1 A method for prognosing therapeutic effectiveness of acute angina pectoris with nitroglycerin and a kit therefor
08/02/2007WO2007085087A1 Vasopressin pathway polymorphisms as indicators of subject outcome in critically ill subjects
08/02/2007WO2007085086A1 A composition including a silicone-based polymer and a method of treating skin disorders using the composition
08/02/2007WO2007085067A1 Pharmaceutical compositions containing docetaxel and a degradation inhibitor and a process for obtaining the same.
08/02/2007WO2007085042A1 Novel lactams
08/02/2007WO2007085036A1 Treatment of friedreich' s ataxia
08/02/2007WO2007076127A3 Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators
08/02/2007WO2007071753A3 S-omeprazole magnesium
08/02/2007WO2007070760A3 Compounds which modulate the cb2 receptor
08/02/2007WO2007070667A3 Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
08/02/2007WO2007069925A3 Non-neurotoxic recreational drugs and a method of treating recreational drug abuse
08/02/2007WO2007068841A3 Use of a composition based on tretinoin, hydroquinone and fluocinolone acetonide, accompanied by a chemical peeling
08/02/2007WO2007068776B1 Antitumour compounds
08/02/2007WO2007068487A3 Tumour treatment with treg down-regulating active agents
08/02/2007WO2007068394A3 Diphenyl urea derivatives
08/02/2007WO2007068070A3 Composition containing an inhibitor of phosphodiesterase iii and a therapeutic alcohol for the treatment of atherosclerosis diseases
08/02/2007WO2007066127A3 Thieno ( 3 , 2-c) pyridine compounds
08/02/2007WO2007065713A3 Use of 8-alpha-ergolines for the treatment of traumatic brain disorders
08/02/2007WO2007065684A3 Bicyclic heteroyclic compounds as antiinflammatory or antiallergic agents
08/02/2007WO2007065437A3 Modulation of the p2y2 receptor pathway
08/02/2007WO2007065289A3 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders
08/02/2007WO2007064658A9 Safe and effective methods of administering therapeutic agents
08/02/2007WO2007059953A8 Formulation comprising a polyphenol-containing composition and isomaltulose
08/02/2007WO2007059950A3 Dry powder pharmaceutical formulations of purine a2a agonists
08/02/2007WO2007059905A3 Thienopyrimidines treating inflammatory diseases
08/02/2007WO2007059230A3 Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
08/02/2007WO2007057691A3 Therapeutic uses of steroidal compounds
08/02/2007WO2007057201A3 Pharmaceutical composition free from dexpanthenol, calcium ions, and phosphate, and use of calcium chelating agent and ophthalmologically compatible viscosity regulator
08/02/2007WO2007056151A3 Protein kinase inhbitors
08/02/2007WO2007054717A3 STAUROSPORINE DERIVATIVES FOR THE TREATMENT OF LEUKEMIA CHARACTERISED BY A SPTBNl -FLT3 MUTATION
08/02/2007WO2007053915A3 Naringenin derivatives with selectivity on ers
08/02/2007WO2007053131A3 Acrylamide derivatives as antibiotic agents
08/02/2007WO2007052104A3 Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-but oxy]-3,4-dihydro-1h-[1,8]naphthyridin-2-one
08/02/2007WO2007052073A3 Heterocycle substituted amide and sulfur amide derivatives as histone deacetylase (hdac) inhibitors
08/02/2007WO2007048220A3 Trazodone composition for once a day adminisitiation
08/02/2007WO2007047724A3 Compositions for lowering serum cholesterol and/or triglycerides
08/02/2007WO2007047722A3 Methods for treating disorders associated with hyperlipidemia in a mammal
08/02/2007WO2007047692A3 Devices, systems and methods for improving memory and/or cognitive function through brain delivery of sirna
08/02/2007WO2007047378A3 Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist
08/02/2007WO2007044937A3 Compositions and methods to modulate memory
08/02/2007WO2007041482A3 Topical anesthetic for dental procedures
08/02/2007WO2007039883A3 Process for preparation of aprepitant
08/02/2007WO2007035121A3 Isoflavones for treating mucopolysaccharidoses
08/02/2007WO2007034009A3 Use of maslinic acid as an antiparasitic agent against phylum apicomplexa protozoans
08/02/2007WO2007032962A3 Compositions and methods for intranasal delivery of tricyclic cannabinoids
08/02/2007WO2007031440A3 2-aniline-4-aryl substituted thiazole derivatives
08/02/2007WO2007030761A3 Acyclic 1,4-diamines and uses thereof
08/02/2007WO2007030454A3 Mutations and polymorphisms of hdac9
08/02/2007WO2007027775A3 Methods for use in modulating mir-122a
08/02/2007WO2007027612A3 Solid particulate tadalafil having a bimodal particle size distribution
08/02/2007WO2007027494A3 Morphous solid dispersions of 7-chloro-n,n, 5-trimethyl-4-oxo-3-phenyl-3, 5,-dihydro-4h-pyridazino [4, 5-b] indole-1-acetamide
08/02/2007WO2007024863A3 Methods and formulations for modulating lyn kinase activity and treating related disorders
08/02/2007WO2007024745A3 Phosphorus-containing macrocycles
08/02/2007WO2007017469A3 Process for preparing an angiotensin ii receptor antagonist
08/02/2007WO2007016979A3 NOVEL HETEROCYCLIC NF-κB INHIBITORS
08/02/2007WO2007011762A8 Jnk inhibitors for the treatment of endometreosis
08/02/2007WO2007002973A3 Use of stilbene derivatives for the production of medicaments for the treatment of solid tumours
08/02/2007WO2006137100A3 Molecular complex comprising arbutine, ascorbic acid, oleuropeina or its derivatives thereof and related uses in medical field
08/02/2007WO2006135713A3 Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators and a farnesyl transferase inhibitor
08/02/2007WO2006135545A3 A method for the prevention and/or treatment of neurodegenerative diseases characterized by administering an ep1 receptor antagonist
08/02/2007WO2006133391A3 Improved treatment for anemia using a hif-alpha stabilising agent
08/02/2007WO2006131925A3 Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
08/02/2007WO2006130676A3 Inhibition of neuronal damage
08/02/2007WO2006127815A3 Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
08/02/2007WO2006121919A3 Methods of treating obsessive compulsive disorder
08/02/2007WO2006113304A3 Combinations, methods and compositions for treating cancer
08/02/2007WO2006112549A8 Fused heterocyclic compound
08/02/2007WO2006105442A3 Spirocyclic heterocyclic derivatives and methods of their use
08/02/2007WO2006105255A3 Cancer vaccines and therapeutic methods
08/02/2007WO2006083366A3 Preparation of ginkgolide and f-seco-ginkgolide lactols
08/02/2007WO2006081391A3 Compounds for inflammation and immune-related uses
08/02/2007WO2006073361A9 Novel pyridine compounds
08/02/2007WO2006060190A3 Imidazole derivatives
08/02/2007WO2006052767A3 Compositions and methods for stabilizing liposomal camptothecin formulations
08/02/2007WO2006048427A8 Method for producing chiral 8-(3-amino-piperidin-1-yl)-xanthines
08/02/2007WO2006048017A8 Lipid-based drug delivery systems containing unnatural phospholipase a2 degradable lipid derivatives and the therapeutic uses thereof
08/02/2007WO2006045096A3 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
08/02/2007WO2006037501A9 Alkil-pyridines as 11-beta inhibitors for diabetes
08/02/2007WO2005096781A3 Methods and compositions for treating gain-of-function disorders using rna interference
08/02/2007WO2005084329A3 Method for inhibiting tumor formation and growth
08/02/2007WO2005055736A3 Compositions of marine botanicals to provide nutrition to aging and environmentally damaged skin
08/02/2007WO2005011595A3 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
08/02/2007WO2004091519A3 Methods of preventing or treating respiratory conditions